- $20.94bn
- $20.39bn
- $937.39m
- 70
- 12
- 100
- 63
2020 February 1st | 2021 January 30th | 2022 January 29th | 2023 January 28th | 2024 February 3rd | |
---|---|---|---|---|---|
Period Length: | 52 W | 52 W | 52 W | 52 W | 53 W |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 120 | 250 | 428 | 653 | 937 |
Cost of Revenue | |||||
Gross Profit | 71.5 | 175 | 304 | 470 | 690 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 348 | 459 | 782 | 912 | 1,261 |
Operating Profit | -228 | -209 | -354 | -259 | -323 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -225 | -210 | -354 | -244 | -283 |
Provision for Income Taxes | |||||
Net Income After Taxes | -225 | -210 | -355 | -247 | -287 |
Net Income Before Extraordinary Items | |||||
Net Income | -225 | -210 | -355 | -247 | -287 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -225 | -210 | -355 | -247 | -287 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.45 | -0.411 | -0.7 | -0.48 | -0.447 |